Wire · operational-macro
FDA approves Enspryng for at‑home TED treatment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
The FDA has approved Genentech's Enspryng as the first at-home subcutaneous treatment option for adults with thyroid eye disease, allowing self-administration every four weeks in the maintenance phase. This approval is supported by positive results from the phase 3 SatraGO programme and highlights its safety and efficacy, marking a significant advance for TED treatment options.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 16 Oct 2026 and 26 Oct 2026.
◆ ◆ The Wire takeaway
You need to reassess your product delivery model if you treat autoimmune diseases. Enspryng’s shift to at-home dosing shows patient convenience can unlock new market access and reshape treatment standards.
◆ Coverage
4 sources · first reported 16 Oct 2026 · latest 26 Oct 2026
◆ Related on Wire
◆ Topics